Page 783 - Williams Hematology ( PDFDrive )

758 Part VI: The Erythrocyte <CN>: <CT> PB

234. Fucharoen S, Winichagoon P: Hemoglobinopathies in southeast Asia: Molecular biol- 269. Brittenham GM, Griffith PM, Nienhuis AW, et al: Efficacy of deferoxamine in prevent-
ogy and clinical medicine. Hemoglobin 21:299, 1997. ing complications of iron overload in patients with thalassemia major. N Engl J Med
235. Agarwal S, Gulati R, Singh K: Hemoglobin E-beta thalassemia in Uttar Pradesh. Indian 331:567, 1994.
Pediatr 34:287, 1997. 270. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al: Survival and complications in
236. Khanh NC, Thu LT, Truc DB, et al: Beta-thalassemia/haemoglobin E disease in Viet- patients with thalassemia major treated with transfusion and deferoxamine. Haemato-
nam. J Trop Pediatr 36:43, 1990. logica 89:1187, 2004.
237. De Silva S, Fisher CA; Members of the Sri Lanka Thalassaemia Study, et al: Thalas- 271. St Pierre TG, Clark PR, Chua-Anusorn W: Measurement and mapping of liver iron
saemia in Sri Lanka: Implications for the future health burden of Asian populations. concentrations using magnetic resonance imaging. Ann N Y Acad Sci 1054:379, 2005.
Lancet 355:786, 2000. 272. Pennell DJ: T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad
238. Olivieri NF, Muraca GM, O’Donnell A, et al: Studies in haemoglobin E beta-thalas- Sci 1054:373, 2005.
saemia. Br J Haematol 141:388, 2008. 273. Lucarelli G, Giardini C, Baronciani D: Bone marrow transplantation in beta-thalas-
239. Premawardhena A, Fisher CA, Olivieri NF, et al: Haemoglobin E beta thalassaemia in semia. Semin Hematol 32:297, 1995.
Sri Lanka. Lancet 366:1467, 2005. 274. Lucarelli G, Giardini C, Baronciani D: Bone marrow transplantation in thalassemia.
240. Fisher CA, Premawardhena A, De Silva S, et al: The molecular basis for the thalas- Semin Hematol 32:297, Review, 1995.
saemias in Sri Lanka. Br J Haematol 121:1, 2003. 275. Di Bartolomeo P, Di Girolamo G, Olioso P, et al: The Pescara experience of allogenic bone
241. Sonakul D, Suwanagool P, Sirivaidyapong P, Fucharoen S: Distribution of pulmonary marrow transplantation in thalassemia. Bone Marrow Transplant 19(Suppl 2):48, 1997.
thromboembolic lesions in thalassemic patients, in Thalassemia: Pathophysiology and 276. Argiolu F, Sanna MA, Addari MC, et al: Bone marrow transplantation in thalassemia:
Management, Part A, edited by Fucharoen S, Rowley PT, Paul NW, p 375. Alan R. Liss, The experience of Cagliari. Bone Marrow Transplant 19(Suppl 2):65, 1997.
New York, 1988. 277. Gaziev D, Polchi P, Galimberti M, et al: Graft-versus-host disease following bone mar-
242. Kattamis C, Metaxotou-Mavromati A, Wood WG, et al: The heterogeneity of normal row transplantation for thalassemia: An analysis of incidence and risk factors. Trans-
Hb A2-beta thalassaemia in Greece. Br J Haematol 42: 109, 1979. plantation 63:854, 1997.
243. Schwartz E: The silent carrier of beta thalassemia. N Engl J Med 281:1327, 1969. 278. Lucarelli G, Isgro A, Sodani P, Gaziev J: Hematopoietic stem cell transplantation in
244. Bianco I, Graziani B, Carboni C: Genetic patterns in thalassemia inter-media (constitu- thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2:a011825, 2012.
tional microcytic anemia): Familial, hematologic and biosynthetic studies. Hum Hered 279. Olivieri NF, Weatherall DJ: The therapeutic reactivation of fetal haemoglobin. Hum Mol
27:257, 1977. Genet 7:1655, 1998.
245. Pirastu M, Ristaldi MS, Loudianos G, et al: Molecular analysis of atypical beta-thalas- 280. Swank RA, Stamatoyannopoulos G: Fetal gene reactivation. Curr Opin Genet Dev 8:366,
semia heterozygotes. Ann N Y Acad Sci 612:90, 1990. 1998.
246. Olds RJ, Sura T, Jackson B, et al: A novel delta 0 mutation in cis with Hb Knossos: A 281. Weatherall DJ: Pharmacological treatment of monogenic disease. Pharmacogenomics J
study of different interactions in three Egyptian families. Br J Haematol 78:430, 1991. 3:264, 2003.
248. Schokker RC, Went LN, Bok J: A new genetic variant of beta-thalassaemia. Nature 282. Quek L, Thein SL: Molecular therapies in beta-thalassaemia. Br J Haematol 136:353,
209:44, 1966. 2007.
248. Ohta Y, Yamaoka K, Sumida I, et al: Homozygous delta-thalassemia first discovered in 283. Olivieri NF, Rees DC, Ginder GD, et al: Treatment of thalassaemia major with phenyl-
Japanese family with hereditary persistence of fetal hemoglobin. Blood 37:706, 1971. butyrate and hydroxyurea. Lancet 350:491, 1997.
249. Vella F, Wells RMC, Ager JAM: A haemoglobinopathy involving haemoglobin H and a 284. Sadelain M: Genetic treatment of the haemoglobinopathies: Recombinations and new
new (Q) haemoglobin. Br J Haematol 1:752, 1958. combinations. Br J Haematol 98:248, 1997.
250. Lie-Injo LE, Pillay RP, Thuraisingham V: Further cases of Hb-Q-H disease (Hb Q-al- 285. Dominski Z, Kole R: Restoration of correct splicing in thalassemic pre-mRNA by anti-
pha-thalassemia). Blood 28:830, 1966. sense oligonucleotides. Proc Natl Acad Sci U S A 90:8673, 1993.
251. Milner PF, Huisman THJ: Studies on the proportion and synthesis of haemoglobin G 286. Lan N, Howrey RP, Lee S-W, et al: Ribozyme-mediated repair of sickle beta-globin
Philadelphia in red cells of heterozygotes, a homozygote, and a heterozygote for both mRNAs in erythrocyte precursors. Science 280:1593, 1998.
haemoglobin G and alpha thalassaemia. Br J Haematol 34:207, 1976. 287. Rivella S, Sadelain M: Therapeutic globin gene delivery using lentiviral vectors. Curr
252. Rieder RF, Woodbury DH, Rucknagel DL: The interaction of alpha-thalassaemia and Opin Mol Ther 4:505, 2002.
haemoglobin G Philadelphia. Br J Haematol 32:159, 1976. 288. Persons DA, Nienhuis AW: Gene therapy for the hemoglobin disorders. Curr Hematol
253. Pich P, Saglio G, Camaschella C, et al: Interaction between Hb Hasharon and alpha Rep 2:348, 2003.
thalassemia: An approach to the problem of the number of human alpha loci. Blood 289. Nienhuis AW, Persons DA: Development of gene therapy for thalassemia. Cold Spring
51:339, 1978. Harb Perspect Med 2:a011833, 2012.
254. Higgs DR, Aldridge BE, Lamb J, et al: The interaction of alpha-thalassemia and 290. WHO Working Group: Hereditary anemias: Genetic basis, clinical features, diagnosis
homozygous sickle cell disease. N Engl J Med 306:1441, 1982. and treatment. Bull World Health Organ 60:543, 1982.
255. Embury SH, Dozy AM, Miller J, et al: Concurrent sickle-cell anemia and alpha-thalas- 291. Stamatoyannopoulos G: Problems of screening and counseling in the hemoglobinopa-
semia. N Engl J Med 306:270, 1982. thies, in Proceedings of the IV International Conference on Birth Defects, p 268. Exerpta
256. Olivieri N, Weatherall DJ: Clinical aspects of β thalassemia and related disorders, Medica, Vienna, 1974.
in Disorders of Hemoglobin, 2nd ed, edited by Steinberg MH, Forget BG, Higgs DR, 292. Alter BP: Antenatal diagnosis: Summary of results. Ann N Y Acad Sci 612:237, 1990.
Weatherall DJ, p 357. Cambridge University Press, Cambridge, UK, 2009. 293. Kazazian HH, Phillips JAI, Boehm CD, et al: Prenatal diagnosis of beta-thalassemia
257. Cazzola M, Borgna-Pignatti C, Locatelli F, et al: A moderate transfusion regimen may by amniocentesis: Linkage analysis of multiple polymorphic restriction endonuclease
reduce iron loading in beta-thalassemia major without producing excessive expansion sites. Blood 56:926, 1980.
of erythropoiesis. Transfusion 37:135, 1997. 294. Old JM, Ward RH, Petrou M, et al: First trimester diagnosis for haemoglobinopathies:
258. Propper RD, Cooper B, Rufo RR, et al: Continuous subcutaneous administration of Three cases. Lancet 2:1413, 1982.
deferoxamine in patients with iron overload. N Engl J Med 297:418, 1977. 295. Old JM, Fitches A, Heath C, et al: First trimester fetal diagnosis for haemoglobinopa-
259. Pippard MJ, Callender ST, Letsky EA, Weatherall DJ: Prevention of iron loading in thies: Report on 200 cases. Lancet 2:763, 1986.
transfusion-dependent thalassaemia. Lancet 1:1178, 1978. 296. Cao A, Galanello R, Rosatelli MC: Prenatal diagnosis and screening of the haemoglo-
260. Pippard MJ, Callender ST, Weatherall DJ: Intensive iron-chelation therapy with desfer- binopathies. Clin Haematol 11:215, 1998.
rioxamine in iron loading patients. Clin Sci Mol Med 54:99, 1978. 297. Modell B, Petrou M, Layton M, et al: Audit of prenatal diagnosis for haemoglobin dis-
261. Nienhuis AW: Safety of intensive chelation therapy. N Engl J Med 296:114, 1977. orders in the United Kingdom: The first 20 years. BMJ 315:779, 1997.
262. Olivieri NF, Bunic JR, Chew E, et al: Visual and auditory neurotoxicity in patients 298. Cheung MC, Goldberg JD, Kan YW: Prenatal diagnosis of sickle cell anemia and thalas-
receiving subcutaneous deferoxamine infusions. N Engl J Med 314:869, 1986. semia by analysis of fetal cells in maternal blood. Nat Genet 14:264, 1996.
263. Porter JB, Jawson MS, Huehns ER, et al: Desferrioxamine ototoxicity: Evaluation of risk 299. Hung EC, Chiu RW, Lo YM: Detection of circulating fetal nucleic acids: A review of
factors in thalassaemia patients and guidelines for safe dosage. Br J Haematol 73:403, methods and applications. J Clin Pathol 62:308, 2009.
1989. 300. Kuliev A, Rechitsky S, Verlinsky O, et al: Preimplantation diagnosis of thalassemias. J
264. Olivieri NF, Basran RK, Talbot AL, et al: Abnormal growth in thalassemia major asso- Assist Reprod Genet 15:219, 1998.
ciated with deferoxamine-induced destruction of spinal cartilage and compromise of 301. Kuliev A, Rechitsky S, Verlinsky O, et al: Birth of healthy children after preimplantation
sitting height. Blood 86:482a, 1995. diagnosis of thalassemia. J Assist Reprod Genet 16:201, 1999.
265. Porter JB: Practical management of iron overload. Br J Haematol 115:239, 2001. 302. Cao A, Kan YW: The prevention of thalassemia. Cold Spring Harb Perspect Med
266. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al: Effectiveness and safety of ICL670 in 3:a011775, 2013.
iron-loaded patients with thalassaemia: A randomized, double-blind, placebo-con- 303. Weatherall DJ, Akinyanju O, Fucharoen S, et al: Inherited disorders of hemoglobin,
trolled dose-escalation trial. Lancet 361:1597, 2003. in Disease Control Priorities in Developing Countries, 2nd ed, edited by Jamison DT,
267. Olivieri NF, Brittenham GM: Management of the thalassemias. Cold Spring Harb Per- Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove
spect Med 3:a011767, 2013. P, p 663. Oxford University Press and the World Bank, New York, 2006.
268. Olivieri NF, Nathan DG, MacMillan JH, et al: Survival in medically treated patients 304. A database of human hemoglobin variants and thalassemias. http://globin.bx.psu.edu/
with homozygous beta-thalassemia. N Engl J Med 331:574, 1994. hbvar/

Kaushansky_chapter 48_p0725-0758.indd 758 9/18/15 2:59 PM